4D Pharma PLC, up 37% at 61.45 pence, 12-month range 24.46p-135.00p. The pharmaceutical company says its therapeutic treatment MRx0518, in combination Merck's Keytruda, met its primary efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback